Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exscientia Plc - American Depositary Shares (NQ:EXAI)

4.840 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exscientia Plc - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
From Exscientia plc
Via Business Wire
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
From Exscientia plc
Via Business Wire
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
From Exscientia plc
Via Business Wire
A Preview Of Exscientia's Earnings
 
Via Benzinga
Barclays Maintains Overweight Rating for Exscientia: Here's What You Need To Know
 
Via Benzinga
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
From Exscientia plc
Via Business Wire
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
From Exscientia plc
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
National Instruments, Nutex Health And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Exscientia Business and Financial Update for the Full Year 2022
From Exscientia
Via Business Wire
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
From Exscientia plc
Via Business Wire
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
From Exscientia plc
Via Business Wire
Exscientia Announces Expansion of its Precision Oncology Pipeline
From Exscientia plc
Via Business Wire
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia plc
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
BP, Hertz Global, Take-Two Interactive Software And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
From Exscientia plc
Via Business Wire
US Stocks Open Lower; Dow Drops 125 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 125 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.37% to 33,960.34 while the NASDAQ fell... 
Via Benzinga
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
From Exscientia plc
Via Business Wire
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Exscientia Business and Financial Update for the Third Quarter 2022
From Exscientia plc
Via Business Wire
Earnings Scheduled For November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million. 
Via Benzinga
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
From Exscientia plc
Via Business Wire
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
From Exscientia plc
Via Business Wire
Exscientia Expands Biologics Design Capability with Automated Laboratory
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in November
From Exscientia
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.